Literature DB >> 14702227

Heterogeneity of outcomes in schizophrenia. 3-year follow-up of treated prevalent cases.

Mirella Ruggeri1, Antonio Lasalvia, Michele Tansella, Chiara Bonetto, Maria Abate, Graham Thornicroft, Liliana Allevi, Paola Ognibene.   

Abstract

BACKGROUND: Care for people with schizophrenia should address a wide range of outcomes, including professional and consumer perspectives. AIMS: To measure changes in psychopathology, functioning, needs for care and quality of life; to develop predictive models for each outcome domain; and to assess the frequency of 'good'and'poor' outcomes, as defined in a series of different definitions that use combinations of the four domains measured.
METHOD: Three-year follow-up of a 1-year-treated prevalence cohort of 107 patients with an ICD-10 diagnosis of schizophrenia attending the South Verona community-based mental health service.
RESULTS: Mean symptom severity and some types of needs for care worsen, but quality of life shows no change. Functioning shows a non-significant trend to deteriorate. Between 32% and 42% of the variance in the four key outcomes was explained by our model. Different definitions of 'good'and 'poor' outcome included 0-31% of patients, depending on the definition used.
CONCLUSIONS: The 3-year outcome for schizophrenia depends on the domain of outcome used, whether staff or patient ratings are used and the stringency of the definitions used for good and poor outcome.

Entities:  

Mesh:

Year:  2004        PMID: 14702227     DOI: 10.1192/bjp.184.1.48

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  9 in total

1.  A randomized-controlled trial of intensive case management emphasizing the recovery model among patients with severe and enduring mental illness.

Authors:  S O'Brien; J McFarland; B Kealy; A Pullela; J Saunders; W Cullen; D Meagher
Journal:  Ir J Med Sci       Date:  2012-01-05       Impact factor: 1.568

2.  The Camberwell assessment of need as an outcome measure in routine mental health care.

Authors:  Erik Wennström; Frits-Axel Wiesel
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-06-14       Impact factor: 4.328

3.  The use of the Camberwell Assessment of Need in treatment: what unmet needs can be met?

Authors:  Marjan Drukker; Kim van Dillen; Maarten Bak; Ron Mengelers; Jim van Os; Philippe Delespaul
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-05       Impact factor: 4.328

4.  Deconstructing the 'black box' of the Camberwell assessment of need score in mental health services evaluation.

Authors:  Erik Wennström; Lars Berglund; Johan Lindbäck; Frits-Axel Wiesel
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-04-21       Impact factor: 4.328

5.  Family interventions for schizophrenia in Italy: randomized controlled trial.

Authors:  Giuseppe Carrà; Cristina Montomoli; Massimi Clerici; Carlo Lorenzo Cazzullo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-02       Impact factor: 5.270

Review 6.  Schizophrenia outcomes in the 21st century: A systematic review.

Authors:  Peter Huxley; Anne Krayer; Rob Poole; Louise Prendergast; Sanjaya Aryal; Richard Warner
Journal:  Brain Behav       Date:  2021-05-15       Impact factor: 2.708

7.  The cumulative needs for care monitor: a unique monitoring system in the south of the Netherlands.

Authors:  Marjan Drukker; Maarten Bak; Joost à Campo; Ger Driessen; Jim Van Os; Philippe Delespaul
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-07-02       Impact factor: 4.328

8.  Schizophrenia in real life: courses, symptoms and functioning in an Italian population.

Authors:  Maria Cristina Turola; Gloria Comellini; Anna Galuppi; Maria Giulia Nanni; Emanuela Carantoni; Chiara Scapoli
Journal:  Int J Ment Health Syst       Date:  2012-10-09

9.  Assessment of the priority target group of mental health service networks within a nation-wide reform of adult psychiatry in Belgium.

Authors:  Vincent Lorant; Adeline Grard; Chantal Van Audenhove; Eva Helmer; Joke Vanderhaegen; Pablo Nicaise
Journal:  BMC Health Serv Res       Date:  2016-05-17       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.